Rocket Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held on May 20, 2026. The filing details the voting outcomes for four proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Shareholders representing approximately 74.02% of eligible outstanding shares (80,774,659 shares) participated in the meeting. All four proposals were approved:
- Proposal One (Election of Directors): Seven directors were elected. Notably, David P. Southwell received a significant number of withheld votes (20,112,032) compared to other nominees, though he was still approved.
- Proposal Two (Ratification of Auditors): Stockholders ratified the appointment of EisnerAmper LLP as the independent registered accounting firm for the fiscal year ending December 31, 2026.
- Proposal Three (Executive Compensation): The non-binding advisory vote on executive compensation was approved.
- Proposal Four (Stock Option Exchange Program): The proposed stock option exchange program was approved, though it received a higher number of votes against (17,615,213) compared to the other proposals.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of the voting results.
Key Facts for Investor Verification
- Verify the specific terms of the approved Stock Option Exchange Program in the 2026 Proxy Statement, given the notable opposition votes.
- Review the 2026 Proxy Statement for details on the compensation package approved in Proposal Three.
- Monitor the Board composition following the election, specifically regarding the significant vote withholding for director David P. Southwell.
- Confirm the engagement scope of EisnerAmper LLP for the 2026 fiscal year.